Early Changes of Tissue Perfusion After Tissue Plasminogen Activator in Hyperacute Ischemic Stroke

被引:10
|
作者
An, Hongyu [1 ]
Ford, Andria L. [4 ]
Vo, Katie [5 ]
Eldeniz, Cihat [1 ]
Ponisio, Rosana [4 ]
Zhu, Hongtu [2 ]
Li, Yimei [2 ]
Chen, Yasheng [1 ]
Powers, William J. [3 ]
Lee, Jin-Moo [4 ]
Lin, Weili [1 ]
机构
[1] Univ N Carolina, Dept Radiol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA
[4] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA
关键词
cerebral perfusion; hypoperfusion; ischemic stroke; reperfusion; tPA; MIDDLE CEREBRAL-ARTERY; HIGH-RESOLUTION MEASUREMENT; TRACER BOLUS PASSAGES; BLOOD-FLOW; CLINICAL RECOVERY; WEIGHTED MRI; RECANALIZATION; DIFFUSION; THROMBOLYSIS; OCCLUSION;
D O I
10.1161/STROKEAHA.110.590323
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-It is hypothesized that tissue plasminogen activator rescues brain tissue by improving perfusion. In this study, we aimed to examine acute regional perfusion changes and how they influence infarction and clinical outcome. Methods-Three sequential MR scans were performed in 15 tissue plasminogen activator-treated patients within 3.5 (tp1), at 6 hours (tp2), and at 1 month (tp3) after stroke onset. "Hypoperfusion" was defined if mean transit time prolongation was more than a threshold (4 thresholds: 3, 4, 5, and 6 seconds). Four regions of interest were classified: (1) "reperfusion"-hypoperfused at tp1, normal at tp2; (2) "nonreperfusion"-hypoperfused at tp1 and tp2; (3) "normal perfusion"-normal at tp1 and tp2; and (4) "new hypoperfusion"-normal at tp1 and hypoperfused at tp2. Risk of infarction was calculated within each region of interest. Associations between tissue perfusion changes and clinical variables were evaluated using stepwise multiple linear regressions. Moreover, the association between National Institutes of Health Stroke Scale changes and perfusion alterations was assessed using linear mixed effect models. Results-Regardless of the mean transit time threshold chosen, the risk of infarction in nonreperfused regions (40% to 68%, thresholds 3 to 6 seconds) was higher than reperfused regions (9% to 30%, P < 0.05), and it was higher in new hypoperfusion regions (9% to 33%) than normal perfusion regions (3% to 4%, P < 0.05). Volume of new hypoperfusion was significantly associated with onset-to-treatment time and initial hypoperfused volume. Overall relative reperfusion was significantly associated with National Institutes of Health Stroke Scale improvement. Conclusion-Early tissue perfusion changes influenced final tissue fate. The development of new hypoperfusion may result from delay in tissue plasminogen activator and a large initial lesion. (Stroke. 2011;42:65-72.)
引用
收藏
页码:65 / 72
页数:8
相关论文
共 50 条
  • [1] Early Changes in Tissue Perfusion After Tissue Plasminogen Activator Administration in Hyperacute Ischemic Stroke: Initial Experiences With Arterial Spin Labeling Perfusion Magnetic Resonance Imaging-Two Case Reports
    Rahmah, Nunung Nur
    Horiuchi, Tetsuyoshi
    Kusano, Yoshikazu
    Seguchi, Tatsuya
    Hanaoka, Yoshiki
    Aoyama, Tatsuro
    Hongo, Kazuhiro
    NEUROLOGIA MEDICO-CHIRURGICA, 2013, 53 (04) : 213 - 216
  • [2] Hyperacute stroke therapy with tissue plasminogen activator
    Alberts, MJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (4C): : D29 - D34
  • [3] Tissue plasminogen activator for acute ischemic stroke
    Qureshi, N
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (21): : 1406 - 1406
  • [4] Clinical Deterioration and Early Imaging Changes after Intravenous Tissue Plasminogen Activator Administration in Acute Ischemic Stroke Patients
    Chou, Claudia
    Bourekas, Eric C.
    Slivka, Andrew
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (07): : 1823 - 1827
  • [5] Recombinant tissue plasminogen activator for acute ischemic stroke
    Al-Buhairi, AR
    Jan, MM
    SAUDI MEDICAL JOURNAL, 2002, 23 (01) : 13 - 19
  • [6] Tissue plasminogen activator for acute ischemic stroke—is it for the elderly?
    Robert J Wityk
    Nature Clinical Practice Neurology, 2008, 4 : 416 - 417
  • [7] Tissue Plasminogen Activator Gene Expression in Ischemic Stroke
    Jickling, Glen
    Ander, Bradley
    Zhan, Xinhua
    Lapchak, Paul
    Sharp, Frank
    NEUROLOGY, 2010, 74 (09) : A445 - A445
  • [8] TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE
    MARLER, JR
    BROTT, T
    BRODERICK, J
    KOTHARI, R
    ODONOGHUE, M
    BARSAN, W
    TOMSICK, T
    SPILKER, J
    MILLER, R
    SAUERBECK, L
    JARRELL, J
    KELLY, J
    PERKINS, T
    MCDONALD, T
    RORICK, M
    HICKEY, C
    ARMITAGE, J
    PERRY, C
    THALINGER, K
    RHUDE, R
    SCHILL, J
    BECKER, PS
    HEATH, RS
    ADAMS, D
    REED, R
    KLEI, M
    HUGHES, S
    ANTHONY, J
    BAUDENDISTEL, D
    ZADICOFF, C
    RYMER, M
    BETTINGER, I
    LAUBINGER, P
    SCHMERLER, M
    MEIROSE, G
    LYDEN, P
    RAPP, K
    BABCOCK, T
    DAUM, P
    PERSONA, D
    BRODY, M
    JACKSON, C
    LEWIS, S
    LISS, J
    MAHDAVI, Z
    ROTHROCK, J
    TOM, T
    ZWEIFLER, R
    DUNFORD, J
    ZIVIN, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24): : 1581 - 1587
  • [9] ROLE OF EMERGENCY TISSUE PLASMINOGEN ACTIVATOR IN ISCHEMIC STROKE
    Alhejaily, Mohammed Ahmed
    Almutairi, Majed Meshal
    Alzaidi, Ahmad Abdulghani
    Alshehri, Fahad Abdullah Ali
    Alaql, Abdulrahman Bader
    Almalki, Muhammad Abdullah M.
    Almasabi, Mohammed Ahmed
    Alhamyani, Abdulmajeed Hamed
    Abuhalimeh, Faisal Fawzi
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (01): : 2667 - 2670
  • [10] Tissue plasminogen activator for acute ischemic stroke - is it for the elderly?
    Wityk, Robert J.
    NATURE CLINICAL PRACTICE NEUROLOGY, 2008, 4 (08): : 416 - 417